synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Wax, used in the packaging of frozen foods, among others, paraffin wax, derived from petroleum oil. Sulfur and its derivative sulfuric acid. Hydrogen sulfide is a product of sulfur removal from petroleum fraction. It is oxidized to elemental sulfur and then to sulfuric acid. Bulk tar and asphalt. Petroleum coke, used in speciality carbon products or as solid fuel.
=== Queen's Police Medal (QPM) === England and Wales Anthony Richard Bayliss, Detective Superintendent, Warwickshire Constabulary. Frank Joseph Breen, Detective Constable, Thames Valley Police. Michael Briggs, Commander, Metropolitan Police. Eileen Margaret Eggington, Detective Chief Superintendent, Metropolitan Police. Christopher Fox, Assistant Chief Constable (designated), Warwickshire Constabulary. William Griffiths, Commander, Metropolitan Police. Gareth Jones, lately Detective Superintendent, North Wales Police. David Robertson Kenworthy, Assistant Chief Constable (designated), Avon and Somerset Constabulary. Paul Joseph Scott-Lee, Assistant Chief Constable (designated), Suffolk Constabulary. Roger John Manning, Chief Superintendent, Staffordshire Police. Graham Moore, Assistant Chief Constable (designated), Cambridgeshire Constabulary. Terence Raymond Nicholls, Constable, Metropolitan Police. Robin Edgar Norman Oake, Chief Constable, Isle of Man Constabulary. Peter John Picken, Superintendent (Divisional Commander), West Mercia Constabulary. Colin Potts, Chief Inspector (Divisional Commander), Greater Manchester Police. Gordon Michael Rogers, lately Chief Superintendent, Wiltshire Constabulary. Roger Edward Sandall, Chief Superintendent (Divisional Commander), Norfolk Constabulary. Richard Owen Thomas, Assistant Chief Constable (designated), Gwent Constabulary. Scotland Andrew Gibson Brown, Assistant Chief Constable, Lothian and Borders Police. John Orr, , Chief Constable, Strathclyde Police. William Rae, Chief Constable, Dumfries and Galloway Constabulary.
=== Early political career === According to Lad's published biography, he began his political career through the Sandur municipal council in 2002. He contested the 2004 Karnataka Legislative Assembly election from the Sandur constituency as a candidate of the Janata Dal (Secular). He defeated Congress candidate V. Y. Ghorpade, receiving 65,600 votes against Ghorpade's 30,022, a margin of 35,578 votes. Lad subsequently joined the Indian National Congress in 2007.
In January 1877 Eddy spurned an approach from Daniel Spofford, and to everyone's surprise married another of her students, Asa Gilbert Eddy. Eddy already believed that her former student and business partner Richard Kennedy was plotting against her. Weeks after the wedding Spofford was suspected too. She had hinted in October 1876 that he might be a successor, but instead he was expelled from the Christian Scientists' Association for "immorality" after quarrelling with her over money. She filed lawsuits against him and others for royalties or unpaid tuition fees. McClure's wrote that Eddy required "absolute and unquestioning conformity" from her students. The conviction that she was at the center of plots and counter-plots became a feature of Eddy's life. She believed that several students were using what she called "malicious animal magnetism," or evil thought, against her. (She also referred to it as An. Mag., Mes., M.A.M., m.a.m., mesmerism, malicious mesmerism, animal magnetism, mental malpractice, malicious malpractice, and mental influence.) Wilson writes that the concept of malicious animal magnetism was an important one in Christian Science. In 1881 Eddy added a 46-page chapter on it, "Demonology", to Science and Health. From the 16th edition in 1886, when James Henry Wiggin became the book's editor, the chapter was reduced and renamed, and in the final edition is a seven-page chapter called "Animal Magnetism Unmasked". Eddy spoke openly about it, including to the press.
Sources: en.wikipedia.org
. This tensor may be expressed as the sum of the viscous stress tensor minus the hydrostatic pressure. The negative of the stress tensor is sometimes called the pressure tensor, but in the following, the term "pressure" will refer only to the scalar pressure. According to the theory of general relativity, pressure increases the strength of a gravitational field (see stress–energy tensor) and so adds to the mass-energy cause of gravity. This effect is unnoticeable at everyday pressures but is significant in neutron stars, although it has not been experimentally tested.
== Sites of synthesis == Leptin is produced primarily in the adipocytes of white adipose tissue. It also is produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal muscle, stomach (the lower part of the fundic glands), mammary epithelial cells, bone marrow, gastric chief cells, and P/D1 cells.
Jan Jozef van Deemter (31 March 1918 – 10 October 2004) was a Dutch physicist and engineer known for the Van Deemter equation in chromatography. He obtained his doctorate in physics from the University of Amsterdam in June of 1950. Starting in 1947 he began work for Royal Dutch Shell as a researcher and it was there that he developed and published his article in 1956.
Sources: en.wikipedia.org
== Cancer == The role of copper in angiogenesis associated with different types of cancers has been investigated. A copper chelator, tetrathiomolybdate, which depletes copper stores in the body, is under investigation as an anti-angiogenic agent in pilot and clinical trials. The drug may inhibit tumor angiogenesis in hepatocellular carcinoma, pleural mesothelioma, colorectal cancer, head and neck squamous cell carcinoma, breast cancer, and kidney cancer. The copper complex of a synthetic salicylaldehyde pyrazole hydrazone (SPH) derivative induced human umbilical endothelial cell (HUVEC) apoptosis and showed anti-angiogenesis effect in vitro. The trace element copper had been found promoting tumor growth. Several evidence from animal models indicates that tumors concentrate high levels of copper. Meanwhile, extra copper has been found in some human cancers. Recently, therapeutic strategies targeting copper in the tumor have been proposed. Upon administration with a specific copper chelator, copper complexes would be formed at a relatively high level in tumors. Copper complexes are often toxic to cells, therefore tumor cells were killed, while normal cells in the whole body remained alive for the lower level of copper. Researchers have also recently found that cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, has been implicated as a breakthrough in the treatment of cancer and has become a new treatment strategy. Some copper chelators get more effective or novel bioactivity after forming copper-chelator complexes.
The In-N-Out menu consists of three burger varieties: hamburger, cheeseburger, and "Double-Double" (two hamburger patties and two slices of cheese). French fries and fountain drinks are available, as well as three flavors of milkshakes. The hamburgers come with lettuce, tomato, with or without onions (the customer is asked upon ordering, and may have them fresh or grilled), and a sauce, which is called "spread" (a Thousand Island dressing variant). There are additional named items not on the menu, but available at every In-N-Out. These variations reside on the chain's "secret menu", though the menu is accessible on the company's website. These variations include 3×3 (which has three patties and three slices of cheese), 4×4 (four patties and four slices of cheese), Neapolitan shakes, grilled cheese sandwich (consists of the same ingredients as the burgers except the meat, plus two slices of melted cheese), Protein Style (wrap with lettuce; consists of the same ingredients as the burgers except buns), and Animal Style (cooked in a thin layer of mustard, adding condiments including pickles, grilled onions, and extra spread). Animal Style fries come with two slices of melted cheese, spread, and grilled onions on top. Whole or sliced chili peppers are also available by request. Both Protein and Animal Style are house specialties that the company has trademarked because of their association with the chain.
This approach falls below international standards, where adverse action is a purely objective test. By contrast in CFMEU v Clermont Coal Pty Ltd an employer was found liable for selecting a union organiser named Mr Scott for redundancy, ostensibly on the basis of "attitude", but where all supervisor's assessments of "attitude" came from Scott's role in union organising, and Scott had an objectively better work record than others scored higher.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.